(KYMR) Kymera Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 7.040m USD | Total Return: 163.8% in 12m
Industry Rotation: -15.9
Avg Turnover: 38.6M
EPS Trend: -35.8%
Qual. Beats: 1
Rev. Trend: -26.9%
Qual. Beats: 1
Warnings
Share dilution 21.7% YoY
Interest Coverage Ratio -937.6 is critical
Altman Z'' -10.68 < 1.0 - financial distress zone
Tailwinds
Leader, Confidence
Kymera Therapeutics Inc (KYMR) is a clinical-stage biopharmaceutical company focused on targeted protein degradation (TPD). The firm utilizes a proprietary platform to develop small molecule therapeutics that direct the bodys ubiquitin-proteasome system to eliminate specific disease-causing proteins rather than simply inhibiting their function. This modality is particularly relevant for undruggable targets where traditional small molecule inhibitors have historically failed to achieve clinical efficacy.
The companys pipeline includes KT-621, an oral STAT6 degrader in Phase 2b trials for multiple inflammatory conditions, and KT-485, an IRAK4 degrader currently in Phase 2 development through a strategic partnership with Sanofi S.A. In addition to its immunology programs, Kymera is advancing oncology candidates, such as its CDK2 degrader, targeting solid tumors. The biotechnology sector often relies on such large-scale pharmaceutical collaborations to offset high R&D costs and leverage global distribution networks during the clinical trial process.
Investors may find ValueRay useful for further analyzing these clinical milestones and partnership structures. Headquartered in Watertown, Massachusetts, Kymera continues to transition its lead candidates through mid-stage human trials to validate its TPD platform across diverse therapeutic areas.
- Clinical trial data readouts for KT-621 in atopic dermatitis and asthma
- Sanofi partnership milestones and IRAK4 program development progress
- Expansion of oral protein degrader pipeline into high-value autoimmune indications
- R&D expenditure levels and cash runway for late-stage clinical advancement
- Regulatory approval pathways for first-in-class STAT6 and IRF5 degrader molecules
| Net Income: -315.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.15 > 0.02 and ΔFCF/TA 11.51 > 1.0 |
| NWC/Revenue: 1.19k% < 20% (prev 750.6%; Δ 444.0% < -1%) |
| CFO/TA -0.15 > 3% & CFO -242.6m > Net Income -315.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (97.5m) vs 12m ago 21.69% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.98% > 50% (prev 6.41%; Δ -2.43% > 0%) |
| Interest Coverage Ratio: -937.6 > 6 (EBITDA TTM -306.1m / Interest Expense TTM 336k) |
| A: 0.37 (Total Current Assets 677.4m - Total Current Liabilities 62.6m) / Total Assets 1.67b |
| B: -0.68 (Retained Earnings -1.14b / Total Assets 1.67b) |
| C: -0.24 (EBIT TTM -315.0m / Avg Total Assets 1.29b) |
| D: -8.81 (Book Value of Equity -1.14b / Total Liabilities 129.4m) |
| Altman-Z'' Score: -10.68 = D |
Over the past week, the price has changed by -5.27%, over one month by -8.35%, over three months by -6.39% and over the past year by +163.81%.
- StrongBuy: 14
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 118.3 | 48.4% |
P/B = 4.599
Revenue TTM = 51.5m USD
EBIT TTM = -315.0m USD
EBITDA TTM = -306.1m USD
Long Term Debt = 80.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 80.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -570.5m USD (recalculated: Debt 80.5m - CCE 650.9m)
Enterprise Value = 6.47b USD (7.04b + Debt 80.5m - CCE 650.9m)
Interest Coverage Ratio = -937.6 (Ebit TTM -315.0m / Interest Expense TTM 336k)
EV/FCF = -26.52x (Enterprise Value 6.47b / FCF TTM -244.0m)
FCF Yield = -3.77% (FCF TTM -244.0m / Enterprise Value 6.47b)
FCF Margin = -474.1% (FCF TTM -244.0m / Revenue TTM 51.5m)
Net Margin = -612.2% (Net Income TTM -315.1m / Revenue TTM 51.5m)
Gross Margin = unknown ((Revenue TTM 51.5m - Cost of Revenue TTM 2.02m) / Revenue TTM)
Tobins Q-Ratio = 3.88 (Enterprise Value 6.47b / Total Assets 1.67b)
Interest Expense / Debt = 0.08% (Interest Expense 61.0k / Debt 80.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -248.9m (EBIT -315.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.81 (Total Current Assets 677.4m / Total Current Liabilities 62.6m)
Debt / Equity = 0.05 (Debt 80.5m / totalStockholderEquity, last quarter 1.54b)
Debt / EBITDA = 1.86 (negative EBITDA) (Net Debt -570.5m / EBITDA -306.1m)
Debt / FCF = 2.34 (negative FCF - burning cash) (Net Debt -570.5m / FCF TTM -244.0m)
Total Stockholder Equity = 1.26b (last 4 quarters mean from totalStockholderEquity)
RoA = -24.35% (Net Income -315.1m / Total Assets 1.67b)
RoE = -25.02% (Net Income TTM -315.1m / Total Stockholder Equity 1.26b)
RoCE = -23.52% (EBIT -315.0m / Capital Employed (Equity 1.26b + L.T.Debt 80.5m))
RoIC = -19.76% (negative operating profit) (NOPAT -248.9m / Invested Capital 1.26b)
WACC = 11.69% (E(7.04b)/V(7.12b) * Re(11.82%) + D(80.5m)/V(7.12b) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 11.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 25.49%
[DCF] Fair Price = unknown (Cash Flow -244.0m)
EPS Correlation: -35.81 | EPS CAGR: 6.37% | SUE: 1.02 | # QB: 1
Revenue Correlation: -26.94 | Revenue CAGR: 33.86% | SUE: 2.20 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.76 | Chg30d=+15.76% | Revisions=+58% | Analysts=21
EPS next Quarter (2026-09-30): EPS=-1.03 | Chg30d=-12.27% | Revisions=-37% | Analysts=20
EPS current Year (2026-12-31): EPS=-3.56 | Chg30d=+1.11% | Revisions=+43% | GrowthEPS=+3.6% | GrowthRev=+104.3%
EPS next Year (2027-12-31): EPS=-4.37 | Chg30d=-9.05% | Revisions=-20% | GrowthEPS=-22.9% | GrowthRev=-51.1%
[Analyst] Revisions Ratio: +58%